CCR2 and neoplasm: Indeed, tumor-produced nitrosylated CCL2, which is the main ligand for CCR2 [62], has been shown to selectively recruit myeloid-derived suppressor cells (MDSCs) while abrogating recruitment of Th1 and cytotoxic T lymphocytes [46, 61, 63].